Skip to main content

Global News

Pfizer's COVID-19 vaccine: What you need to know

41604991630_TBVACCINEPFIZER.jpg
41604991630_TBVACCINEPFIZER.jpg
Advertisement
KUALA LUMPUR:On Monday, Pfizer and its German partner BioNTech announced preliminary results that suggested their vaccine was more than 90 percent effective, according to early data from it’s Phase 3 study.

The study involved 43,538 participants with 42 percent having diverse backgrounds, and no serious safety concerns have been observed, while safety and additional efficacy data continue to be collected.

ABOUT THE VACCINE
  • It uses a never-before-approved technology called messenger RNA, or mRNA, to produce an immune response in people who are vaccinated.
  • The mRNA vaccine approach uses genetic material called mRNA to trick cells into producing bits of protein that look like pieces of the virus.
  • The immune system learns to recognize and attack those bits and, in theory, would react fast to any actual infection.
WHEN IS THE VACCINE READY?
  • Pfizer and BioNTech are continuing to accumulate safety data. They plan to submit data from the full Phase 3 trial for scientific peer-review publication.
  • Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November 2020.
  • Based on current projections, Pfizer and BioNTech expect to produce up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

WHAT ARE THE CHALLENGES? 
  • The main issue is that the vaccine, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, needs to be kept at minus 70 degrees Celsius or below.
  • Pfizer said the company was working closely with the US government and state officials on how to ship the vaccine from its distribution centers in the United States, Germany and Belgium around the globe.
  • The detailed plan includes using dry ice to transport frozen vaccine vials by both air and land at their recommended temperatures for up to 10 days.

Must Watch Video